Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX81 Nirogacestat
D11453 Nirogacestat hydrobromide (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Antineoplastics, Miscellaneous
Nirogacestat
D11453 Nirogacestat hydrobromide (USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG03016 Nirogacestat
D11453 Nirogacestat hydrobromide
DG01639 CYP2C19 substrate
DG03016 Nirogacestat
D11453 Nirogacestat hydrobromide
DG01644 CYP2D6 substrate
DG03016 Nirogacestat
D11453 Nirogacestat hydrobromide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03016 Nirogacestat
D11453 Nirogacestat hydrobromide
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Aspartic peptidases
Presenilin family
PSEN1/PSENEN/NCSTN/APH1A
D11453 Nirogacestat hydrobromide (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11453
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11453
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11453
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG03016 Nirogacestat
DG01639 CYP2C19 substrate
DG03016 Nirogacestat
DG01644 CYP2D6 substrate
DG03016 Nirogacestat
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03016 Nirogacestat